Selinexor
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Selinexor: From Oncology Use to Drug-Induced Osteoporosis
One-Sentence Summary
Selinexor is an oral anticancer drug (an XPO1/exportin-1 inhibitor), but the data compiled for this report do not list a specific approved indication. The TxGNN model predicts it may be relevant for drug-induced osteoporosis, with 0 clinical trials and 0 publications currently supporting this direction. The prediction rests only on a computational score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the compiled data |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.22% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (the single NDA is cancelled) |
| Number of NDAs | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Selinexor is generally known as an XPO1 (exportin-1) inhibitor, which blocks the nuclear export of regulatory proteins. A possible link to bone biology would run through nuclear export of regulators involved in osteoclast and osteoblast signaling. This is speculative and not supported by the supplied data.
There is also a caution. Selinexor is associated with nausea, anorexia, weight loss, fatigue and cytopenias, which could plausibly worsen bone health in frail oncology patients. No evidence shows that it treats or prevents drug-induced osteoporosis. The high TxGNN score (0.992) is a computational prediction, not clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| NDA212306 (cancelled) | XPOVIO (Karyopharm Therapeutics Inc.) | Film-coated tablet (oral) | Not listed in the compiled data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (XPO1 inhibitor); this classification is inferred from the drug’s known pharmacology, not from the compiled data |
| Myelosuppression Risk | Cytopenias are reported as an associated adverse effect; please refer to the package insert warnings and precautions for severity |
| Emetogenicity Classification | Nausea and anorexia are associated adverse effects; please refer to the package insert warnings and precautions |
| Monitoring Items | CBC (with differential), body weight and nutritional status; please refer to the package insert for the full list |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: 81 interactions were identified in the DDI screening. Examples of those rated Major:
- Deferiprone
- Samarium (153Sm) lexidronam
- Adalimumab
- Baricitinib
- Certolizumab pegol
- Cladribine
- Clozapine
Moderate examples include strontium chloride Sr-89, roflumilast, chloramphenicol, zidovudine, azathioprine, alemtuzumab, anakinra, and several vaccines. Many of these involve myelosuppressive or immunosuppressive combinations.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score, with no clinical trials or publications. The only US NDA is cancelled. Package insert safety data and mechanism data are missing, and the drug’s known adverse effects could plausibly worsen bone health.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (blocking for safety screening)
- Mechanism of action data (for example from DrugBank) to assess any biological link to bone remodeling
- Preclinical or observational evidence on selinexor’s effect on bone
- Confirmation of the original approved indication and the reason for the NDA cancellation
- Route and formulation compatibility assessment for the proposed indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.